Mehrdad Saadat
Optometrist · Lithia Springs, GANPI 1659469674
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,885 of the $9,319 with a category attached, or 84.6%. 25 manufacturers reported payments, led by Alcon at 29.9% of the total. Among optometrist clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 241 payments — averaging $38.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$3K
- Johnson & Johnson Vision Care, Inc.$840
- Coopervision Inc.$684
- Sun Pharmaceutical Industries Inc.$655
- Optos, Inc.$607
- Tarsus Pharmaceuticals, Inc.$496
- plus $3K from 19 others
Across 24 payments — averaging $43.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Notal Vision, Inc.$1K
What the payments were for
- Travel & lodging$8289%
- Food & beverage$7,88585%
- Entertainment$6077%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 76 | $2,784 |
| Johnson & Johnson Vision Care, Inc. | 18 | $840 |
| Coopervision Inc. | 17 | $684 |
| Sun Pharmaceutical Industries Inc. | 12 | $655 |
| Optos, Inc. | 7 | $607 |
| Tarsus Pharmaceuticals, Inc. | 16 | $496 |
| Amgen(2 entities) | 13 | $489 |
| Bausch & Lomb Americas Inc. | 13 | $415 |
| AbbVie(2 entities) | 8 | $356 |
| Dompe US, Inc. | 6 | $273 |
| Glaukos Corporation | 4 | $241 |
| Novartis | 12 | $220 |
| Lombart Brothers, Inc. | 6 | $206 |
| Oyster Point Pharma, Inc. | 7 | $190 |
| Kala Pharmaceuticals, Inc. | 4 | $186 |
| Biotissue Holdings Inc. | 6 | $139 |
| Harrow Eye, LLC | 4 | $125 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $96 |
| Sight Sciences, Inc. | 1 | $90 |
| Ivantis, Inc | 1 | $88 |
| Maculogix, Inc. | 1 | $42 |
| Visioneering Technologies, Inc. | 3 | $39 |
| Quidel Corporation | 1 | $23 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $20 |
| Carl Zeiss Meditec USA, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DAILIES$1,317
- AIR OPTIX$648
- OCT OPHTHALMOSCOPE$504
- PANORAMIC OPHTHALMOSCOPE$504
- CEQUA$457
- Acuvue$372
- NFC-700$252
- TEPEZZA$249
- TOTAL30$240
- MyDay Contact Lens$238
- P200DTx$225
- P200T$225
- P200TE$225
- P200TxE$225
- Precision7$152
- Precision 1$127
- RADIUS$127
- Oxervate$125
- INFUSE$124
- XDEMVY$124
How this compares
$9,319 in reported general payments places this provider in the 95th percentile of 1,285 optometrist providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 33 | $48,465 |
| XdemvyLotilaner | 20 | $37,961 |
| TyrvayaVarenicline Tartrate | 35 | $34,473 |
| XiidraLifitegrast | 22 | $25,470 |
| LumiganBimatoprost | 27 | $19,601 |
| Loteprednol Etabonate | 26 | $4,229 |
| Latanoprost | 128 | $1,107 |
| Prednisolone Acetate | 18 | $940 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 90 | $915 |
| Timolol Maleate | 38 | $237 |
| ValacyclovirValacyclovir Hcl | 13 | $198 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 13 | $133 |
| Brimonidine Tartrate | 14 | $78 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $356 | $68,06560 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $496 | $37,96120 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $190 | $34,47335 claims |
| Bausch & Lomb Americas Inc.Xiidra | $415 | $25,47022 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $96 | $4,22926 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,285 optometrist providers in Georgia.
Other optometrist in Lithia Springs
- Joshua JohnstonAtlanta$993K
- John WomackCanton$931K
- Naheed AhmadRoswell$296K
- Scott MoscowRoswell$278K
- Stephen SummerowPerry$222K
- Janelle DavisonSmyrna$199K
- Keyle BrownDawsonville$182K
- Nacondus GambleFort Stewart$175K
- Amber ZaunbrecherAtlanta$99K
- Jeffrey CofieWarner Robins$93K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.